Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 3

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 3
---
xley Act of
2002 dated as of this filing in connection with this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2 hereto.

Except as described in Note 2, no other information included in the Q3 2024 Form
10-Q is being amended or updated by this Amendment and, other than as described herein, this Amendment does not purport to reflect any
information or events subsequent to the Q3 2024 Form 10-Q. This Amendment continues to describe the conditions as of the date of the Q3
2024 Form 10-Q and, except as expressly contained herein, we have not updated, modified or supplemented the disclosures contained in the
Q3 2024 Form 10-Q. Accordingly, this Amendment should be read in conjunction with the Q3 2024 Form 10-Q and with our filings with the
SEC subsequent to the Q3 2024 Form 10-Q.

<div align='center'>RENOVARO INC. AND SUBSIDIARIES

- INDEX -</div>

|                                 |                                                                                                                          | Page |
| PART I – FINANCIAL INFORMATION: |                                                                                                                          |    1 |
| Item 1.                         | Restated Financial Statements (Unaudited):                                                                               |    1 |
|                                 | Restated Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited)                                          
 and June 30, 2023                                                                                                        |    2 |
|                                 | Restated Condensed Consolidated Statements of Operations for the Three and                                               
 Nine Months Ended March 31, 2024, and 2023 (Unaudited)                                                                   |    3 |
|                                 | Restated Condensed Consolidated Statements of Comprehensive Loss for the Three                                           
 and Nine Months Ended March 31, 2024, and 2023 (Unaudited)                                                               |    4 |
|                                 | Condensed Consolidated Statements of Stockholders’ Equity for the Nine Months Ended March 31, 2024, and 2023 (Unaudited) |    5 |
|                                 | Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2024, and 2023 (Unaudited)           |    7 |
|                                 | Notes to the Condensed Consolidated Financial Statements (Unaudited)                                                     |    8 |
|